Basilea Pharmaceutica Ltd. ("Basilea") successfully completed a capital increase from authorized capital and set the placement price of CHF 45.75 per new share. A total of 1,000,000 new shares were sold in an accelerated bookbuilding to institutional investors. Accordingly, Basilea raised gross proceeds of CHF 45.75 million. Cantor Fitzgerald, Credit Suisse and Bryan Garnier acted as Joint Bookrunners in this PIPE transaction.
Basilea intends to use the net proceeds for i) the clinical development of Basilea's clinical oncology drug candidates derazantinib and lisavanbulin, ii) pre-clinical research and development activities, and iii) working capital and other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.
The new shares will be admitted to trading on the International Reporting Standard segment of SIX Swiss Exchange as of February 26, 2021.
Baker McKenzie advised Basilea Pharmaceutica Ltd. on all legal aspects of the this PIPE transaction. The Baker McKenzie team consisted of Matthias Courvoisier (Partner, Capital Markets), Philip Spoerlé (Senior Associate, Capital Markets), Yves Mauchle (Senior Associate, Capital Markets) and Jan Lusti (Junior Associate, Capital Markets) as well as U.S.-qualified capital markets partner Adam Farlow.